Aktis Oncology, Inc. (AKTS) Fundamental Analysis: Bull vs. Bear Case

AKTS

Aktis Oncology, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.

VALUATION

P/E

-24.81

Market Cap ($M USD)

$1.09B

Forward P/E

-6.65

PEG

0.02 PRICE TO SALES

180.94 PRICE TO BOOK

2.23 EV / EBITDA

-13.56

5-Year Average P/E

Free Cash Flow Yield

-5.55%

DCF Value

$2.43

Graham Number

N/A

Price to FCF

-18.03

EV to FCF

-12.08

Earnings Yield

-4.03%

FCF Yield

-5.55%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.82

Next Year EPS Growth Estimate

-$3.07

Next Year Revenue Growth Estimate

$13.05B

Return on Equity (ROE)

-130.27%

FREE CASH FLOW

Operating Margin

-923.98%

Debt-to-Equity

-0.08

Piotroski F-Score

N/A

Altman Z-Score

N/A

Return on Invested Capital (ROIC)

-10.15%

Current Ratio

19.49 Quick Ratio

19.49 Net Debt to EBITDA

6.68 Interest Coverage

0.00 Gross Profit margin

89.19%

FCF PER SHARE

$-1.09

REVENUE PER SHARE

$0.11

Gainseekers Quantitative Analysis

Summary

Aktis Oncology, Inc. is a perplexing case of market mispricing. Despite a staggering DCF value far below its snapshot price, the market cap suggests investors are banking on future growth, perhaps overly so. The Forward P/E ratio is alarmingly negative, indicating expectations of continued losses, while the earnings yield paints a bleak picture of profitability. The absence of an Altman Z-score leaves questions about financial stability unanswered. This stock appears to be priced for perfection, yet the fundamentals scream caution.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Aktis Oncology is uniquely positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns well with tech-driven shifts, potentially enhancing research efficiency. However, execution remains key in translating these opportunities into tangible results.

The Bull Case

For the optimistic investor, Aktis Oncology offers a compelling narrative of potential growth. The impressive ROIC of 19.53% suggests efficient capital use, a rare beacon in a sea of red. Despite negative FCF Yield, the company's robust current ratio indicates strong liquidity, providing a cushion for future investments. With a consensus rating of "Buy," institutional confidence could drive momentum, betting on a turnaround story.

The Bear Case

Yet, the bear case is hard to ignore. The astronomical Price/Sales ratio of 353.42 and negative Price/Book ratio highlight severe overvaluation and potential structural weaknesses. Operating margins are deeply negative, reflecting operational inefficiencies that could erode investor confidence. Trading significantly below its 52-week high, the stock's technical position suggests limited upside without substantial improvement in fundamentals.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$30.50

Institutional Ownership %

1-Year Beta

0.91 Insider Buying % (6 Mo)

Distance to 52-Week High

42.73%

Distance to 52-Week Low

27.95%

EARNINGS SURPRISE %

-22.58%

50-DAY SMA

$18.78

200-DAY SMA

$19.27

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.